BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19181511)

  • 1. Lung function in 30-year-old alpha-1-antitrypsin-deficient individuals.
    Bernspång E; Wollmer P; Sveger T; Piitulainen E
    Respir Med; 2009 Jun; 103(6):861-5. PubMed ID: 19181511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory symptoms and lung function in 30-year-old individuals with alpha-1-antitrypsin deficiency.
    Bernspång E; Sveger T; Piitulainen E
    Respir Med; 2007 Sep; 101(9):1971-6. PubMed ID: 17532199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years.
    Piitulainen E; Mostafavi B; Tanash HA
    Int J Chron Obstruct Pulmon Dis; 2017; 12():495-500. PubMed ID: 28203073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung function and CT lung densitometry in 37- to 39-year-old individuals with alpha-1-antitrypsin deficiency.
    Mostafavi B; Diaz S; Piitulainen E; Stoel BC; Wollmer P; Tanash HA
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3689-3698. PubMed ID: 30510411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CT lung densitometry in young adults with alpha-1-antitrypsin deficiency.
    Bernspång E; Diaz S; Stoel B; Wollmer P; Sveger T; Piitulainen E
    Respir Med; 2011 Jan; 105(1):74-9. PubMed ID: 20674322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Swedish α1-Antitrypsin Screening Study: Health Status and Lung and Liver Function at Age 34.
    Tanash HA; Nystedt-Düzakin M; Montero LC; Sveger T; Piitulainen E
    Ann Am Thorac Soc; 2015 Jun; 12(6):807-12. PubMed ID: 25803183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The liver in 30-year-old individuals with alpha(1)-antitrypsin deficiency.
    Bernspång E; Carlson J; Piitulainen E
    Scand J Gastroenterol; 2009; 44(11):1349-55. PubMed ID: 19891586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung Function and CT Densitometry in Subjects with alpha-1-Antitrypsin Deficiency and Healthy Controls at 35 Years of Age.
    Piitulainen E; Montero LC; Nystedt-Düzakin M; Stoel BC; Sveger T; Wollmer P; Tanash HA; Diaz S
    COPD; 2015 Apr; 12(2):162-7. PubMed ID: 25280185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical course and prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ).
    Tanash HA; Nilsson PM; Nilsson JA; Piitulainen E
    Thorax; 2008 Dec; 63(12):1091-5. PubMed ID: 18682522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory symptoms and lung function in young adults with severe alpha(1)-antitrypsin deficiency (PiZZ).
    Piitulainen E; Sveger T
    Thorax; 2002 Aug; 57(8):705-8. PubMed ID: 12149531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival benefit of lung transplantation in individuals with severe α1-anti-trypsin deficiency (PiZZ) and emphysema.
    Tanash HA; Riise GC; Hansson L; Nilsson PM; Piitulainen E
    J Heart Lung Transplant; 2011 Dec; 30(12):1342-7. PubMed ID: 21821433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung Function and Health Status in Individuals with Severe Alpha-1-Antitrypsin Deficiency at the Age of 42.
    Schramm GR; Mostafavi B; Piitulainen E; Wollmer P; Tanash HA
    Int J Chron Obstruct Pulmon Dis; 2021; 16():3477-3485. PubMed ID: 34992356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ.
    Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R; Fähndrich S
    Respir Med; 2017 Sep; 130():1-8. PubMed ID: 29206626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver function in alpha-1-antitrypsin deficient individuals at 37 to 40 years of age.
    Mostafavi B; Diaz S; Tanash HA; Piitulainen E
    Medicine (Baltimore); 2017 Mar; 96(12):e6180. PubMed ID: 28328804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results after lung volume reduction surgery in patients with alpha1-antitrypsin deficiency.
    Tutic M; Bloch KE; Lardinois D; Brack T; Russi EW; Weder W
    J Thorac Cardiovasc Surg; 2004 Sep; 128(3):408-13. PubMed ID: 15354100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD.
    Green CE; Vayalapra S; Hampson JA; Mukherjee D; Stockley RA; Turner AM
    Thorax; 2015 Oct; 70(10):939-45. PubMed ID: 26141072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of smoking and intermediate alpha 1-antitrypsin deficiency (PiMZ) on lung function.
    Eriksson S; Lindell SE; Wiberg R
    Eur J Respir Dis; 1985 Oct; 67(4):279-85. PubMed ID: 3878302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits.
    Tanash HA; Ekström M; Rönmark E; Lindberg A; Piitulainen E
    Eur Respir J; 2017 Sep; 50(3):. PubMed ID: 28889108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspects of treatment in alpha 1-antitrypsin deficiency: insights derived from a Swedish PiZZ series.
    Eriksson S; Wu MC
    Eur Respir J Suppl; 1990 Mar; 9():39s-43s. PubMed ID: 2340050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ).
    Piitulainen E; Eriksson S
    Eur Respir J; 1999 Feb; 13(2):247-51. PubMed ID: 10065663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.